{"id":69441,"date":"2026-07-06T14:55:00","date_gmt":"2026-07-06T06:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=69441"},"modified":"2026-07-06T14:55:00","modified_gmt":"2026-07-06T06:55:00","slug":"novartis-to-acquire-myricx-bio-for-1-1-billion-to-strengthen-adc-pipeline-with-novel-n-myristoyltransferase-inhibitor-payload-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69441","title":{"rendered":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novartis<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced an agreement to acquire <strong>Myricx Bio<\/strong>, a privately held UK-based biotechnology company pioneering a new class of <strong>antibody-drug conjugates (ADCs)<\/strong> utilizing <strong>N-myristoyltransferase inhibitor (NMTi) payloads<\/strong>. The transaction, valued at <strong>USD 1.1 billion upfront<\/strong> with up to <strong>USD 400 million in potential milestone payments<\/strong>, represents a strategic expansion of Novartis&#8217; oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Novartis (NYSE: NVS)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Myricx Bio (UK-based private biotech)<\/td><\/tr><tr><td><strong>Technology Focus<\/strong><\/td><td>N-myristoyltransferase inhibitor (NMTi) payload ADCs<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 1.1 billion<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 400 million<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 1.5 billion<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>H2 2026<\/td><\/tr><tr><td><strong>Conditions<\/strong><\/td><td>Regulatory approvals and customary closing conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-myricx-bio-technology-platform-amp-pipeline\" class=\"wp-block-heading\">Myricx Bio Technology Platform &amp; Pipeline<\/h2>\n\n\n\n<h3 id=\"h-core-innovation\" class=\"wp-block-heading\">Core Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Payload Class:<\/strong> N-myristoyltransferase inhibitors (NMTi) \u2013 novel mechanism distinct from traditional TOPO-1 inhibitors<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Designed to address key limitations of commonly used ADC payload classes including resistance mechanisms and toxicity profiles<\/li>\n\n\n\n<li><strong>Targeted Delivery:<\/strong> Precision tumor cell targeting with enhanced cancer-killing potency<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lead-development-assets\" class=\"wp-block-heading\">Lead Development Assets<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Indication Focus<\/th><th>Development Stage<\/th><th>Competitive Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>B7-H3<\/strong><\/td><td>Multiple solid tumors<\/td><td>Preclinical\/IND-enabling<\/td><td>Emerging target with broad tumor expression and limited competition<\/td><\/tr><tr><td><strong>HER2<\/strong><\/td><td>Multiple solid tumors<\/td><td>Preclinical\/IND-enabling<\/td><td>Established target with opportunity for improved therapeutic index vs. existing HER2 ADCs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-for-novartis\" class=\"wp-block-heading\">Strategic Rationale for Novartis<\/h2>\n\n\n\n<h3 id=\"h-oncology-portfolio-enhancement\" class=\"wp-block-heading\">Oncology Portfolio Enhancement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Leadership:<\/strong> Strengthens Novartis&#8217; position in the rapidly expanding ADC market, projected to exceed $20 billion by 2030<\/li>\n\n\n\n<li><strong>Payload Diversification:<\/strong> Adds novel NMTi payload class to complement existing pipeline assets<\/li>\n\n\n\n<li><strong>Target Expansion:<\/strong> B7-H3 represents emerging high-value target with potential across multiple tumor types<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Acquires proprietary NMTi payload technology for future pipeline applications beyond lead assets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Dynamics:<\/strong> Intense competition driving need for differentiated payload mechanisms and improved therapeutic indices<\/li>\n\n\n\n<li><strong>TOPO-1 Limitations:<\/strong> Current standard payload class faces challenges with resistance development and dose-limiting toxicities<\/li>\n\n\n\n<li><strong>Novartis Positioning:<\/strong> Complements existing oncology portfolio including marketed products and late-stage pipeline assets<\/li>\n\n\n\n<li><strong>Innovation Gap:<\/strong> Addresses industry-wide need for next-generation ADC technologies with novel mechanisms of action<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-development-implications\" class=\"wp-block-heading\">Financial &amp; Development Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Investment:<\/strong> Significant capital allocation demonstrates confidence in NMTi payload platform potential<\/li>\n\n\n\n<li><strong>Timeline Acceleration:<\/strong> Acquisition provides immediate access to advanced preclinical assets vs. internal development timelines<\/li>\n\n\n\n<li><strong>Geographic Expansion:<\/strong> UK biotech acquisition enhances Novartis&#8217; European innovation footprint<\/li>\n\n\n\n<li><strong>Talent Acquisition:<\/strong> Gains specialized ADC and payload development expertise from Myricx team<\/li>\n\n\n\n<li><strong>Pipeline De-risking:<\/strong> Multiple asset approach (B7-H3 + HER2) diversifies development risk<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-amp-integration-considerations\" class=\"wp-block-heading\">Regulatory &amp; Integration Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antitrust Review:<\/strong> Expected to receive routine regulatory scrutiny given Myricx&#8217;s preclinical stage and private status<\/li>\n\n\n\n<li><strong>Integration Strategy:<\/strong> Likely to maintain UK operations as specialized ADC center of excellence within Novartis structure<\/li>\n\n\n\n<li><strong>Development Continuity:<\/strong> Minimal disruption expected to ongoing preclinical programs during integration period<\/li>\n\n\n\n<li><strong>Manufacturing Strategy:<\/strong> Leverages Novartis&#8217; established ADC manufacturing capabilities for rapid clinical translation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition positions Novartis to capitalize on the next wave of ADC innovation, combining Myricx&#8217;s novel NMTi payload technology with Novartis&#8217; global development and commercial infrastructure to address significant unmet needs in solid tumor oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[4834,140,865],"class_list":["post-69441","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-myricx-bio","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis&#039; oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69441\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis&#039; oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69441\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T06:55:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology\",\"datePublished\":\"2026-07-06T06:55:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Myricx Bio\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69441#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69441\",\"name\":\"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-06T06:55:00+00:00\",\"description\":\"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis' oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69441\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69441#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis' oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69441","og_locale":"en_US","og_type":"article","og_title":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology","og_description":"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis' oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.","og_url":"https:\/\/flcube.com\/?p=69441","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T06:55:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69441#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69441"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology","datePublished":"2026-07-06T06:55:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69441"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Myricx Bio","Novartis","NYSE: NVS"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69441#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69441","url":"https:\/\/flcube.com\/?p=69441","name":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-06T06:55:00+00:00","description":"Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company pioneering a new class of antibody-drug conjugates (ADCs) utilizing N-myristoyltransferase inhibitor (NMTi) payloads. The transaction, valued at USD 1.1 billion upfront with up to USD 400 million in potential milestone payments, represents a strategic expansion of Novartis' oncology portfolio into next-generation targeted drug conjugates with differentiated payload mechanisms designed to overcome limitations of current ADC technologies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69441#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69441"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69441#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69441"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69441\/revisions"}],"predecessor-version":[{"id":69442,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69441\/revisions\/69442"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}